ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread
Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the post-hoc analyses of the ARCHES trial (NCT02677896), which…
Related Articles
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
VJOncology – The video journal of oncology
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Highlights in colorectal cancer at ASCO GI 2024
In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening…
Enhancing targeted radionuclide therapy with nanoparticles
Debjani Pal, PhD, Oak Ridge National Laboratory, Oak Ridge, TN, discusses the emergence of targeted radionuclide therapy (TRT) for personalized cancer treatment by delivering radiation…
Remotely delivered cancer genetic testing in the Making Genetic Testing Accessible (MAGENTA) trial
Elizabeth Swisher, MD, University of Washington in Seattle, WA, discusses the MAGENTA (Making Genetic Testing Accessible) trial (NCT02993068), which aimed to make genetic testing more…
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses results from an exploratory analysis of EGFR mutation (EGFRm) dynamics in the Phase III FLAURA2…
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses results from an exploratory analysis of EGFR mutation (EGFRm) dynamics in the Phase III FLAURA2…
KRYSTAL-1: adagrasib with cetuximab in KRAS G12C-mutated CRC
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from an analysis of the Phase I and II…